Familial combined hyperlipidemia (FCHL) may be genetically and metabolically more heterogeneous than previously thought A consistent feature is an increase in circulating very-low-density lipoprotein (VLDL) apolipoprotein (apo) B, which could be due to either an increase in apoB production or a decrease in its catabolism. Therefore, we directly measured VLDL apoB production in the postabsorptive state in seven FCHL subjects (four male, three female) and seven normal control subjects (three male, four female) by using L-[lu C]leucine as an endogenous label. Mean age and body mass index did not differ significantly between the two groups. The mean total cholesterol levels were 4.7±0.8 and 8.8±1.6 mmol/L (±SD, P<.01) and the mean triglyceride levels were 0.84±0.14 and 330±1.10 mmol/L (±SD, P<.01) in the control and FCHL groups, respectively. Although the fractional production rate of VLDL apoB was 38% lower in the FCHL group than in the control subjects (0.11 ±0.03 versus 0.18±0.02 pool/h; mean±SD, P<.01), its absolute production rate was 2.7 times greater (534±193 /ig/kg per hour in FCHL versus 196±71 /tg/kg per hour in control subjects; mean±SD, P<.01). There was a linear relation (r=0.8, P=.O3) between triglyceride levels and the VLDL apoB production rate in FCHL, the slope of which indicated a similar VLDL trigtycerlde-to-apoB ratio in the FCHL and control groups. We conclude that FCHL is a metabolically coherent disorder and that the increase in circulating apoB and triglyceride levels in FCHL is due to secretion of an increased number of VLDL particles, each containing, on average, a normal amount of triglyceride and one molecule of apoB. We hypothesize that FCHL is caused by a defective gene or genes, which enhance intrahepatlc lipid availability for lipoprotein assembly and increase apoB secretion by decreasing the amount of a constitutively synthesized pool of apoB that undergoes Intrahepatic degradation. (Arteriosclerosis and Thrombosis 1993;13:1110-1118 KEY WORDS • stable isotopes • apoB • kinetic studies • VLDL • familial combined hyperlipidemia
F amilial combined hyperlipidemia (FCHL) was described by Goldstein et al 1 in 1973 . It has a population prevalence of 0.5% to 2.0%' and is thought to cause up to 10% of the coronary heart disease occurring before the age of 60 years. 2 Diagnosis is based on finding multiple individuals with different types of primary hyperlipidemia (increases in both cholesterol and trigiyceride or of either lipid alone) within the same pedigree. Although the authors 1 concluded from the original set of families that FCHL is due to a single autosomal dominant gene of reduced penetrance acting primarily on triglyceride levels, a number of analyses have since failed to detect evidence for this mode of inheritance, and it is likely that FCHL has a more complex genetic basis, being due at least in some families to more than one gene. [3] [4] [5] [6] The cause of the mixed hyperlipidemia in FCHL is unknown and may well vary between families. Defects in certain catabolic pathways have been thought to cause FCHL, some cases of which may be due to heterozygous lipoprotein lipase deficiency. 7 There is also evidence from studies in patients 8 and transgenic mice 9 of an association between an increase in apolipoprotein (apo) CHI and combined hyperlipidemia, through either direct inhibition of lipoprotein lipase; displacement from trigryceride-rich lipoproteins of apoCII, the necessary cofactor for lipoprotein lipase; or displacement of apoE that is required for remnant lipoprotein clearance. Moreover, we have previously shown linkage of hyperlipidemia to a gene cluster containing apoCIII in a subset of FCHL families. 10 By contrast, studies using exogenously radiolabeled very-low-density lipoprotein (VLDL) have shown overproduction of VLDL apoB in FCHL. many of the features of FCHL (frequent, though not invariable, increases in circulating lipids; familial clustering; and increased risk of coronary artery disease). 1516 It has, however, been suggested that in FCHL a proportion of the newly secreted apoB-100 is channeled into a pool of small, dense VLDL, which rapidly enters the lowdensity lipoprotein (LDL) compartment, and that this "metabolic channeling" may explain the apparent increase in production of apoB-100. 2 Exogenous labeling of lipoproteins may alter their physicochemical properties and influence their catabolism and cannot be used to directly examine apolipoprotein production. 17 - 19 Endogenous labeling of apolipoproteins with stable-isotope amino acid precursors circumvents some of these problems. 20 To establish whether there is metabolic coherence in FCHL, we have therefore used leucine labeled with the stable isotope 13 C to directly measure apoB-100 production in FCHL and control subjects.
Methods

Isotopes and Chemicals
L-[l- 13 C]leucine (99% 13 C) was obtained from Cambridge Isotope Laboratories, Woburn, Mass. The leucine was dissolved in 150 mmol/L NaCl, packaged into 10-mL ampoules by the local pharmacy, and tested for sterility and freedom from pyrogens. All other chemicals were of analytical grade and were obtained either from Sigma Chemical Co or from BDH Chemical Co, both in Poole, Dorset, England.
Subjects
After a 10-hour overnight fast, seven hyperlipidemic individuals from well-characterized FCHL pedigrees (Fig 1) and seven normolipidemic control subjects were admitted for 1 day to the metabolic ward at Northwick Park Hospital. Clinical and lipid details are shown in Table 1 . In each of the FCHL subjects, hyperlipidemic status was assigned on the basis of the first lipid level the patient had on attending the lipid clinic, since this was taken to be the most unbiased estimate. The control subjects were either normolipidemic spouses of FCHL family members or healthy volunteers. Cholesterol levels were measured by the cholesterol oxidase method, 22 -23 and triglyceride was measured by the Kodak dry-slide method 24 in the hospital clinical laboratory. Plasma apoB concentrations were measured by radioimmunoassay. 25 FCHL subjects had been off all medication known to affect lipid levels for at least 6 weeks before the study. No subjects showed the apo E2/E2 phenotype. All subjects underwent a full physical and biochemical examination to exclude liver, heart, lung, kidney, and thyroid gland dysfunction; all were normoglycemic. All subjects gave informed consent. The study received local ethics committee approval. 21 The percentile classes are £5%; >5% and £25%; >25% and £50%; >50% and £75%; >75% and £90%; >90% and £95%; >95%. "Original" is the absolute and percentile lipid level in the subject at time of first measurement.
•Significantly different from control mean, P<.01.
Experimental Protocol
In each subject, an intravenous line was inserted into a superficial vein of each arm, one for administration of the tracer and the other for access to superficial venous blood, at approximately 6:45 AM. After a priming dose of 8 /imol/kg body weight of L-[ 13 C]leucine, a continuous 9.0-hour infusion of 7 /unol/kg body weight per hour was given (Fig 2) . Subjects fasted overnight from 8 PM and for the duration of the study. Noncaloric drinks were permitted as required. The subjects rested quietly in bed in the metabolic room maintained at thermoneutrality. Five milliliters of blood was taken into heparinized tubes before tracer infusion and thereafter at 30-minute intervals for the remainder of the infusion, beginning after 2 hours (see Fig 2) . After immediate separation by low-speed centrifugation at 4°C in a bench-top centrifuge, the plasma was stored at -70°C for analysis of the degree of I3 C enrichment of plasma a-ketoisocaproic acid (aKIC), the deamination product of leucine. An additional 12 mL of blood was collected hourly in tubes to which 120 jtL of 10% EDTA (final concentration, 1 mg/mL) had been added for VLDL apoB isolation and analysis. All of these blood samples were also separated immediately after collection by low-speed centrifugation at 4°C. Ffty microliters of an equal mixture of 5% NaN 3 and 5% gentamicin was added to each of these plasma samples after separation.
VLDL and ApoB-100 Separation and Quantification
VLDL was separated by ultracentrifugation at a density of 1.006 g/mL for 18 hours at 160 OOOg with an LKB Bromma 2330 ultraspin centrifuge and an SRP 50 AT rotor according to the method of Havel et al. 26 After ultracentrifugation, the VLDL fraction was isolated by tube slicing. ApoB-100 was precipitated with tetramethylurea (TMU) by the method of Packard et al 27 
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B-100 - minutes in an MSE Mistral centrifuge, the infranatant was carefully removed, leaving a disc of apoB-100 precipitate. The precipitate was delipidated by adding 3 mL of a 3:1 vol/vol mixture of ethanol and diethyl ether, mixing, and leaving overnight at 4°C. After centrifugation at 500g for 30 minutes, the supernatant was carefully removed by aspiration, and the precipitate was further delipidated twice with ether and dried over nitrogen at room temperature. 27 From duplicate samples of VLDL, aliquots were subjected to polyacrylamide gradient gel electrophoresis to check for contamination with apoB-48 and freedom from other protein contamination after TMU precipitation (Fig 3) . A known amount of norleucine, a nonphysiological amino acid, was added to each sample, followed by 2.0 mL of 6N HQ. The samples were then transferred to 25-mL tubes with Teflon-lined screw caps (Philip Harris Ltd, London, England), sealed under nitrogen, and incubated at 110°C for 24 hours to completely hydrolyze the apoB-100. The hydrorysate was dried under nitrogen, reconstituted in 0.5 mL of 50% acetic acid, and transferred to a freshly prepared Dowex AG-8X cationic resin column. After washing with deionized water, the amino acids were eluted with 3 mL of 3 mol/L NH4OH into glass Reactivials (Wheaton Ltd, Mays Landing, NJ) and dried under nitrogen. The amino acid residues were reacted with acetonitrile and Af-methyl-N-(ter/-butyldimethylsilyl)triflouroacetamide to form the bis(tert-butyldimethylsilyl) derivative. Plasma aKIC was reacted with pyridine and N,Ofcw(trimethylsilyl)triflouroacetamide to form the O-trimethylsih/lquinoxalinol derivative. 28 Enrichment of both leucine and aKIC was quantified by using a Finnigan 9600 gas chromatograph (GC) interfaced to a Finnigan 4500 quadropole mass spectrometer (MS) run in electron impact mode under computer control. 29 
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Quantification of ApoB-100
The GC/MS method used by us included the measurement of the leucine/norleucine ratio. Since the amount of norleucine that had been added was known, the amount of apoB-100 present in each sample could be measured directly by calculating the amount of leucine present (the leucine content of apoB-100 is H.2% 30 ). The mean of the leucine/norleucine ratio in the five highest recoveries was used to calculate the apoB content of each sample, since this was considered most reliable. However, the leucine/norleucine ratio was similar at lower recoveries, and the VLDL apoB concentration was similar throughout the study. The apoB-100 content of VLDL aliquots was corrected for the plasma volume from which it had been derived. A plasma volume of 45 mL/kg body weight was assumed. 31 The size of the circulating VLDL apoB pool was then obtained by multiplying the circulating plasma volume by the concentration of VLDL apoB in plasma. Pooled plasma samples were used to provide sufficient apoB-100 protein (100 fig) for estimation by the Lowry assay. 32 Random duplicate aliquots of VLDL apoB-100 were assayed by both GC/MS and the Lowry method 32 after TMU precipitation. GC/MS methodology indicated a 95% recovery of apoB-100 when compared with Lowry protein quantification. In addition, TMU precipitates were analyzed for contamination of apoB-100 with other VLDL lipoproteins (Fig 3) . No form of contamination was seen. Experiments (results not shown) revealed that the amount of apoB-100 precipitate formed with TMU varied linearly with total VLDL apoB concentration in plasma aliquots, as did the leucine/norleucine ratio. 33 
Measurement of Stable Isotope Enrichment
Selective ion monitoring of the derivatized samples at a mass to charge ratio (mlz) of 302 for unlabeled norleucine and leucine and mlz 303 for labeled leucine was used to determine isotopic abundance. The atom percent excess (APE) enrichment was calculated using the following formula:
where IR, is the isotope ratio of sample at time /, and IRo is the isotope ratio of sample at zero time (before L-[l- 13 C]leucine administration). The enrichment of plasma aKIC values (precursor pool) was obtained similarly. This method of calculation is equivalent to the method of Cobelli et al. 34 
Calculation of ApoB-100 Production
Apolipoprotein production was measured as the rate of incorporation of l3 C-enriched leucine into circulating VLDL apoB. The fractional production rate of VLDL apoB (measured in pools per hour) was measured as
Rate of Increase of Leucine Enrichment Within ApoB-100 (APE) Enrichment of Precursor Pool (Plasma aKIC) at Plateau (APE)
The slope of the rate of increase in apoB-100 was obtained by regression analysis from 1 to 4 hours in control subjects and 1 to 6 hours in the FCHL patients. The absolute production rate (fractional production rate; FPR) of VLDL apoB was calculated as FPR (Pools Per Hour)xApolipoprotein Pool Size (Milligrams)
Statistical Analysis
Results and clinical details in the two groups were compared by Student's unpaired t test.
Results
Families and Subjects
Families with FCHL were ascertained through a single proband with combined hyperlipidemia who had been referred to the lipid clinic at Northwick Park Hospital. The FCHL family trees are shown in Fig 1. Lipid values in the FCHL subjects studied and the normolipidemic control subjects are shown in Table 1 . All FCHL subjects except subject 12 had at least one relative with both cholesterol and triglyceride levels above the 75th percentile for age and sex on the basis of the data from the Lipid Research Clinics. 21 All of the subjects studied had either cholesterol or trigryceride values above the 95th percentile at the time of original blood sampling, and for all except subjects 8 and 11, both of these values were above the 95th percentile. At the time of the study in subjects 10,11,12, and 13, both lipid levels were above the 95th percentile, subject 8 had a cholesterol level greater than the 95th and a trigryceride level greater than the 75th percentile, subject 9 had a normal cholesterol level but a triglyceride level above the 90th percentile, and subject 14 had a cholesterol level above the 95th and a triglyceride level above the 90th percentile.
All lipid levels in the control population were below the 50th percentile, apart from subjects 2 and 7, in whom the cholesterol and triglyceride levels, respectively, were between the 50th and 75th percentiles. The differences between the lipid levels in the FCHL subjects and the control subjects were significant at the P<.01 level.
The body mass index of the FCHL group was approximately 15% greater than that of the control gTOup, but this difference was not statistically significant.
Kinetic Studies
Subjects were fasted overnight for 10 hours. Triglyceride-rich lipoproteins were prepared from blood taken immediately before and at intervals during the stableisotope infusion as shown in Fig 2. Separation of apolipoproteins by polyacrylamide gel is shown in Fig 3  for samples from a single individual. For this subject and the other subjects in the study, more than 98% of the apoB was in the apoB-100 form at the beginning of and throughout the infusion. This was confirmed for the apoB-100 obtained after TMU precipitation as seen in Fig 3. The other apolipoproteins remained in solution and were not precipitated.
Plasma aKIC 13 C enrichment measured as APE rapidly increased after the infusion commenced, reached a plateau by 2 hours, and remained constant for the duration of the study (Figs 4 and 5) .
The enrichment of 13 C-leucine in VLDL apoB increased in linear fashion soon after the 13 C-leucine infusion was begun. In normolipidemic subjects a plateau was achieved in 13 C-leucine enrichment of VLDL apoB some 6 hours after starting the infusion (Fig 4) . In contrast, in the FCHL subjects a distinct plateau was not obtained, reflecting the increased pool size of VLDL apoB in these subjects (Fig 5) .
The results of kinetic analysis for VLDL apoB are presented in Table 2 . Whereas the mean FPR for VLDL apoB in the FCHL patients (0.110±0.027 pool/ h) was 68% that of the normal control subjects (0.177±0.024 pool/h,/ > <.01), the total apoB-100 pool in the hyperlipidemic group (5180±2123 fig/kg ) was some five times larger than that in the control subjects (1094±327 fig/kg, P<.0l ). This indicates that the absolute production rate of apoB in the FCHL patients (534±193 jig apoB-100/kg per hour) was 3.3 times as great as in the normolipidemic control subjects (196±71 /ig/kg per hour, P<.01).
The rate of VLDL apoB production was plotted against the plasma triglyceride levels for the FCHL subjects and the normal control subjects (Fig 6) . There was a significant linear relation (r=0.8, P=.O3) between the rate of apoB production and triglyceride in the FCHL subjects (Fig 6A) . This relation was not apparent in the normal control subjects (r=0.47, NS). Overall, there was a significant linear relation between apoB production and circulating triglyceride levels (r=0.9, P<m, Fig 6C) . Calculation of the VLDL triglycerideto-apoB-100 ratios for the FCHL and normal subjects gave similar values (/>>.05) of 26.9±6.3 (mean±SD) and 33±11.2, respectively. There were no significant relations between apoB production and plasma cholesterol, body mass index, or age in either group.
FIG 5. Time course of 13 C enrichment (mean±SEM) in very-low-density lipoprotein apolipoprotein B and a-ketoisocaproic add enrichment in seven familial combined hyperlipidemia patients during continuous infusion of L-[l-'
Discussion
Although FCHL is probably more heterogeneous than was originally thought, its constant features are the presence of raised levels of circulating apoB 35 -36 and mixed hyperlipidemia.
-
2 Either increased production or decreased catabolism of apoB-containing lipoproteins could produce this picture. In this study we have therefore used stable isotopes to measure directly the VLDL apoB-100 production in individuals with combined hyperlipidemia from well-defined FCHL kindreds identified through a single proband with cholesterol and triglyceride levels above the 95th percentile who presented to the lipid clinic at our hospital. This study shows that VLDL apoB production is increased approximately threefold in subjects with mixed hyperlipidemia from FCHL pedigrees compared with normal control subjects. Thus, despite debate concerning the genetic basis of FCHL, our results show that there is a metabolically coherent basis for the hyperlipidemia seen in these pedigrees.
In addition, we have demonstrated a direct, linear relation between the rate of VLDL apoB production and serum triglyceride levels in our FCHL subjects ( Fig  6A) . Although apoB-100 and triglyceride have previously been shown to increase at the same time," 14 -37 this linearity has not been reported before. The slope of the regression line indicates that the ratio of VLDL apoB production to serum triglyceride levels is similar in the FCHL and control subjects. If one assumes that each VLDL particle contains only one apoB molecule, then this indicates that in our hyperlipidemic patients the increase in circulating triglyceride is due to an increase in the number of circulating VLDL particles, each of which contains, on average, an amount of triglyceride similar to that of the normal control subjects. Calculation of the triglyceride-to-apoB-100 content of VLDL confirmed that this was similar in FCHL subjects and in agreement with previous work. 35 This observation implies that the hypertriglyceridemia of FCHL is different from that associated with noninsulin-dependent diabetes mellitus, in which there is a differential increase in very large, triglyceride-rich VLDL particles with an increase in the ratio of triglyceride to apoB-100. 38 Our results also differ from those of a study of six carbohydrate-fed patients with moderate hypertriglyceridemia of unspecified etiology, in whom measurements made with '^I-labeled VLDL and [ 3 H]glycerol showed dissociation between the production of triglyceride and that of VLDL apoB. 39 The validity of our results depends on a number of assumptions concerning our stable-isotope method of measuring apoB production. First, there must be virtually complete equilibrium between plasma and intrahepatic aKIC. Second, the level of enrichment of plasma aKIC, and hence intrahepatic aKIC, must accurately reflect the enrichment of the direct precursor of apoB-100, intrahepatic leucine amino acyl tRNA. Although Parhofer et al 40 have recently questioned the validity of using plasma aKIC enrichment as a reflection of the plateau enrichment of apoB-100, their study included only three measurements of aKIC tracer/tracee ratios, in one of which the tracer/tracee ratios of aKIC and apoB-100 at plateau were identical. By contrast, in more extensive studies elsewhere and in those here, we have found the enrichment of plasma aKIC 13 C to be highly correlated with that of leucine apoB-100 at plateau. 41 In addition, Layman and Wolfe 42 have shown that in dogs, plasma aKIC enrichment closely approximated the 13 Cleucine enrichment in the intracellular fluid of a number of tissues, including the liver. Finally, it has been assumed that apoB-100 is homogeneously labeled and that essentially all newly synthesized apoB-100 is secreted. However, studies with primary rat hepatocytes suggest that a proportion of apoB synthesized in the liver is degraded intracellularly and not secreted. 43 Similarly, studies in rat liver with stable isotopes also suggest that there is a pool of apoB-100 that is not readily secreted. 44 Thus, the level of production of apoB-100 measured in turnover studies, whether with exogenous or endogenous labeling, may reflect not the level of absolute hepatic synthesis, but rather the level of secretion or production of apoB from the liver into the circulation.
In humans, VLDL apoB production has been measured with a variety of stable isotopes. approach is most comparable to that of Cohn et al, 20 although we used 13 C as label, while Cohn et al used 3 H, and we measured the plateau 13 C enrichment of plasma aKIC rather than that of apoB-100. Finally, in our study the isotopes were infused for 9 hours rather than the 15 hours used in the study by Cohn et al. This shorter duration did not affect the measurement of apoB-100 production, which was based on linear regression of the slope of apoB-100 enrichment during the first 4 (control subjects) or 6 (FCHL) hours only (Figs 4 and 5) .
The FPRs of our FCHL and control subjects are somewhat lower than those published previously in studies that used endogenously and exogenously labeled lipoproteins (Table 3 ). However, in many of these studies, the number of subjects was small and the spread of results large. The mean FPR in normal individuals published by Cohn and colleagues, 20 whose approach was most similar to our own, was some 29% greater than in our control subjects. The differences between these studies may in part reflect the different methods used to calculate the FPRs. The large number of steps involved in these studies and the different approaches to data handling make standardization between laboratories difficult. It has been claimed 3 *- 40 that calculation of enrichment with stable isotopes in terms of APE is not analogous to specific activity in the case of radioactive tracers. Therefore, we calculated our results as the tracer/tracee ratio as suggested by Cobelli et al. 34 The
FPRs calculated with the tracer/tracee ratio were some 10% less than those calculated using APE in both the FCHL and control groups. Hence, the percent difference between these two groups was the same with both methods of calculation (Table 2) . We used linear regression analysis of the increase in VLDL apoB enrichment to calculate its FPR. Although Cobelli et al 34 and Parhofer et al 40 have questioned this approach, it is the one that has been most commonly used to date in studies of apoB metabolism. 204546 Moreover, Parhofer et al have themselves shown that despite wide intraindividual variation depending on the modeling approach used (linear regression, monoexponential fitting, or multicompartmental modeling), overall estimates of FPRs and total production rates derived with all three methods did not differ significantly.
We undertook these studies to examine whether the metabolic defect in FCHL is anabolic or catabolic and whether this defect varies between families. The need for this was sparked by the controversy surrounding the metabolic and genetic basis of FCHL. In their original description, Goldstein et al 1 concluded that FCHL was a genetic disorder inherited in an autosomal dominant fashion and that anomalies in its inheritance pattern were due to reduced penetrance. Others have suggested a more complex mode of inheritance or even that the apparent clustering of hyperlipidemia in certain families may be due to ascertainment bias. 35 As yet, no overall VLDL, very-low-density lipoprotein; apo, apolipoprotein; FPR, fractional production rate of VLDL apoB; APR, absolute production rate of VLDL apoB; FCHL, familial combined hyperlipidemia. All subjects were fasted. *In the study by Parhofer et al, 40 only four different subjects were investigated, but one of these was studied twice. The only data available represent the pooled results of studies performed with either L-[l- 13 C]leucine or [ 1! N]grycine. tTo calculate precursor enrichment in this study, urinary hippurate enrichment was multiplied by a factor of 0.8. model explains the genetic basis of FCHL, and it is possible that more than one gene is involved in certain families and that different genes may operate in different pedigrees. Biochemical and genetic studies have suggested, for example, that a deficiency of lipoprotein lipase 7 or a defect at the apoAI-CIII-AIV gene locus may be present in some families. 10 Neither the lipoprotein lipase nor apoAI-CIII-AIV loci, either alone or together, explain the phenotype in these families (authors' unpublished results). In the families studied we have not, therefore, established either the genetic basis of the hyperlipidemia or whether one or more genes are involved. Despite this, each of the persons studied showed substantial overproduction of VLDL apoB-100. This is in agreement with previous studies.
1114 - 37 We may, therefore, conclude that for these persons and probably for most individuals with combined hyperlipidemia from FCHL families, there is a metabolically coherent problem involving overproduction of VLDL apoB-100.
Consideration of the regulation of apoB-100 production from liver cells may shed light on the metabolic defect in FCHL. Studies performed mainly in cultured liver cells and hepatoma cells 4748 but supported by studies in intact organ preparations 44 indicate that the apoB gene is constitutively expressed, so that a fixed amount of apoB is produced and that regulation is not at the level of transcription, stabilization of mRNA, or translation. Rather, it has been shown that increased neutral-lipid availability increases the secretion of apoB-100-containing lipoproteins by decreasing the amount of apoB-100 that undergoes presecretional degradation in an endoplasmic reticulum-related compartment. 48 -50 If the results from experimental systems can be extended to the human liver, that is, that apoB-100 synthesis is constitutive and cannot be increased, 47 then our results showing a linear relation between apoB-100 production and serum triglyceride levels are suggestive of a defect in FCHL that decreases the intracellular degradation of the synthesized apoB-100 and maximizes its secretion. A hypothesis to explain this is that the metabolic defect in FCHL leads to increased triglyceride or cholesteryl ester availability and that this, by decreasing intracellular degradation, increases apoB production from the liver. Thus, any gene or set of genes whose products operate within or outside the liver and that ultimately enhances hepatic neutral lipid availability could contribute to the FCHL phenotype.
